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Abstract
Novel plasma metabolite patterns reflective of improved metabolic health (insulin sensitivity, fitness, reduced body weight)
were identified before and after a 14–17 wk weight loss and exercise intervention in sedentary, obese insulin-resistant
women. To control for potential confounding effects of diet- or microbiome-derived molecules on the systemic
metabolome, sampling was during a tightly-controlled feeding test week paradigm. Pairwise and multivariate analysis
revealed intervention- and insulin-sensitivity associated: (1) Changes in plasma xeno-metabolites (‘‘non-self’’ metabolites of
dietary or gut microbial origin) following an oral glucose tolerance test (e.g. higher post-OGTT propane-1,2,3-tricarboxylate
[tricarballylic acid]) or in the overnight-fasted state (e.g., lower c-tocopherol); (2) Increased indices of saturated very long
chain fatty acid elongation capacity; (3) Increased post-OGTT a-ketoglutaric acid (a-KG), fasting a-KG inversely correlated
with Matsuda index, and altered patterns of malate, pyruvate and glutamine hypothesized to stem from improved
mitochondrial efficiency and more robust oxidation of glucose. The results support a working model in which improved
metabolic health modifies host metabolism in parallel with altering systemic exposure to xeno-metabolites. This highlights
that interpretations regarding the origins of peripheral blood or urinary ‘‘signatures’’ of insulin resistance and metabolic
health must consider the potentially important contribution of gut-derived metabolites toward the host’s metabolome.
Citation: Campbell C, Grapov D, Fiehn O, Chandler CJ, Burnett DJ, et al. (2014) Improved Metabolic Health Alters Host Metabolism in Parallel with Changes in
Systemic Xeno-Metabolites of Gut Origin. PLoS ONE 9(1): e84260. doi:10.1371/journal.pone.0084260
Editor: Marc Claret, Institut d’Investigacions Biome`diques August Pi i Sunyer, Spain
Received August 28, 2013; Accepted November 13, 2013; Published January 8, 2014
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This work was supported by USDA-ARS intramural Projects 5306-51530-016-00D and 5306-51530-019-00 (JWN, NLK, SHA), NIH-NIDDK R01DK078328
(OF, NLK, JWN, GH, JF, WTG, CLH, MEH, SHA), NIH 1 U24 DK097154 for the West Coast Metabolomics Center (OF, JWN), and NIH P20 HL113452 (OF). The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sean.h.adams@ars.usda.gov (SHA); ofiehn@ucdavis.edu (OF)
. These authors contributed equally to this work.
Introduction
Pre-diabetes and type 2 diabetes mellitus (T2DM) are defined
by elevated blood glucose following an overnight fast or at 2 hr
following an oral glucose tolerance test (OGTT) [1]; however, a
clinically-significant increase in blood sugar is a late event in
disease progression and is not an optimal prognostic. Identifying
more sensitive T2DM risk markers or those that track deteriorat-
ing insulin sensitivity would have potential value as clinical
diagnostics and would help elucidate the underlying pathophys-
iology. Advancements in metabolomics technologies to interrogate
hundreds of metabolites in human blood or urine hold promise in
this regard. Recent metabolomics studies have highlighted that
human insulin resistance, T2DM, and T2DM risk involve
significant perturbations in lipid and amino acid metabolism in
addition to glucose, as reflected in altered phosphatidylcholine
derivatives, positive associations with blood branched-chain amino
acids (BCAAs), 2-hydroxybutyrate (2-HB), long- and medium-
chain acylcarnitines, and negative associations with blood glycine
and linoleoyl-glycerophosphocholine (L-GPC)[2–16].
Measurement of blood metabolites in the overnight-fasted state,
while valuable, may not unmask subtle phenotypes associated with
insulin resistance or pre-diabetes that manifest when the body’s
metabolic machinery is challenged. Since insulin resistance
involves impairment of normal glucose and insulin homeostasis,
metabolomics analyses following an OGTT are an attractive
means to identify biochemical pathways associated with individual
variability in insulin action and blood sugar control. To our
knowledge, only five studies have reported post-OGTT blood
metabolite profiling in humans [17–21]. These reports highlighted
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that in healthy individuals a glucose challenge with attendant
increases in blood insulin and glucose is accompanied by expected
reductions in plasma indices of lipolysis (e.g., glycerol, long-chain
fatty acids [LCFA]) and LCFA b-oxidation (e.g., chain-shortened
fatty acylcarnitines, b-hydroxybutyrate), and increases in markers
of tissue amino acid utilization (e.g., reductions in blood amino
acids) and glycolysis (e.g. lactate). Interestingly, the OGTT
significantly increased blood bile acid and lysophosphotidylcholine
metabolites, although the etiology of this was not identified
[17,19]. Post-OGTT metabolite patterns have also been com-
pared between normal glucose tolerant (NGT) and impaired
glucose tolerant (IGT) subjects: IGT persons showed blunted post-
OGTT changes in lactate, glycerol and glycerol-3-phosphate, and
leucine/isoleucine [17,20].
We are not aware of any reports examining OGTT-associated
metabolomics to determine longitudinal changes in circulating
metabolite patterns, to test the hypothesis that improvements in
insulin sensitivity or metabolic fitness alter comprehensive
metabolite responses. For instance, one would expect that plasma
markers that positively correlate with insulin resistance or T2DM
in cross-sectional studies (see above) would be reduced by
interventions that increase insulin sensitivity. We examined this
issue in obese sedentary women with modest hyperinsulinemia,
tested before and after a 14–17 week weight loss and fitness
intervention and while fed a controlled diet. A subset of the 321
detected plasma metabolites were altered in the fasted state or
following an OGTT when comparing pre- vs. post-intervention.
Variance in both expected and novel markers, including several
putative xeno-metabolites (i.e., of non-endogenous origin, from
diet and/or gut microbial metabolism), discriminated the pre- vs.
post-intervention condition. One or more of these metabolites may
be useful to track improvements in or deterioration of metabolic
health, and the results point to alterations in gut metabolism or
microbial ecology that occur in response to improvements in host
metabolic health.
Methods
Human Subjects
All protocols were approved by the University of California at
Davis Institutional Review Board, and all subjects provided
informed written consent. The study is listed in ClinicalTrials.gov
(NCT01494025). An important goal of the research was to identify
metabolites that are responsive to changes in insulin sensitivity due
to improvements in fitness and body mass following a diet and
exercise intervention. To this end, obese modestly hyperinsulin-
emic 30–50 year old females were recruited from the greater Davis
and Sacramento, California communities. All participants were
eumenorrheic, non-smoking, and sedentary (typical planned
exercise ,30 min. per week). Body mass index (BMI) was between
30–37.5 kg/m2 and participants reported that they were weight
stable as defined ,5% change in body mass over the past 6
months. Participants were insulin-resistant at the time of screening
as determined by an abbreviated oral glucose tolerance test
(OGTT) that consisted of an initial blood draw (following an
overnight fast) and an additional blood draw 2 hours after
consuming a standard 75 g glucose drink (Fisher Scientific, catalog
#s 401025-FB, 401526-FB, 401223-FB). Insulin resistance was
defined as one or more of the following: (a) as per the American
Diabetes Association guidelines for pre-diabetes, fasting glucose
$100 and ,126 mg/dL or 2-hour OGTT glucose $140 and
,199 mg/dL; and/or (b) a target Quantitative Insulin Sensitivity
Check Index (QUICKI) score ,0.315, Homeostasis Model
Assessment (HOMA) .3.67, or logHOMA .0.085. The latter
criteria were derived using the upper limit of normal fasting
glucose (100 mg/dL) and a serum insulin (15 mU/mL) that
approximates the upper value of the third quartile of 72
normoglycemic men and women tested by the UC Davis Medical
Center (UCDMC) Pathology Laboratory in the course of
establishing their normal ranges for insulin using the ADVIA
Centaur instrument. One subject displayed normal plasma glucose
and a borderline QUICKI score of 0.316, but was included in the
study because she met all other inclusion criteria, had a fasting
insulin of 17 mU/mL and high lipids (cholesterol 266 mg/dL;
triglycerides 440 mg/dL), consistent with an insulin resistance
phenotype. Exclusion criteria included any clinical signs of
infection, chronic disease, personal history of cardiovascular
disease, elevated blood pressure (.130/85), diabetes, regular
medications other than oral contraceptives and pregnancy or
lactation. Out of 511 initial phone screens, a total of 18 subjects
were enrolled, 2 dropped prior to testing, 16 participated through
the first phase of the study, and 1 subject was not compliant with
the prescribed diet provided during either Test Week and was
therefore excluded (Figure S1). Three subjects dropped following
Test Week 1, prior to or during weight loss/exercise intervention,
leaving 12 of 15 starting subjects available for re-examination in
Test Week 2.
Pre- and Post- Intervention Test Week Diet and OGTT
Protocol
Participants completed testing before (‘‘Test Week 1’’) and after
(‘‘Test Week 2’’) an exercise and weight loss intervention (14–17
weeks) designed to improve fitness and insulin sensitivity (described
below). To minimize variability in metabolomics that could be
influenced by differences in diet composition, during Test Week 1
and Test Week 2 the participants were provided standardized
meals and snacks, with foods lot-matched within-subject. Diets
were prescribed to maintain body mass during the specific Test
Week using the DRI equation. Mass was determined daily during
Test Weeks and small changes in prescription calories were made
to maintain body mass within 5%. Study menus were designed by
a registered dietitian and prepared by the WHNRC Metabolic
Food Lab using the University of Minnesota’s Nutrient Data
System for Research (NDS-R) version 2009 and ProNutra
software (Viocare Technologies, Inc.), guided by the 2005 Dietary
Guidelines for Americans (DGs). Menus consisted of primarily
shelf-stable (e.g., frozen, dried, canned) foods (see File S1:
Supplemental Materials 1). For the first 3 d, each subject was
fed Menu 1; for the subsequent 3–5 d, subjects were fed Menu 2.
The average calculated nutrient composition based on the actual
menus provided to the study participants, as well as the targets for
meeting the DG’s 2000-kcal goals are provided in File S1
(Supplemental Materials 1); these targets were confirmed by post
hoc composite analysis of the diet (Covance) During Test Week 1
and Test Week 2, participants were instructed to eat and drink
only what was provided to them by the study team, and
encouraged to eat study meals on site; however, for logistical
reasons (e.g., work schedules) many meals were packed ‘‘to go.’’
Self-reported compliance was determined with daily food diaries
(File S1: Supplemental Materials 1). On specific test days when
participants ate a meal in-house (e.g., following the OGTT
completion), meals were monitored by the Metabolic Food Lab
staff.
A primary aim of the study was to examine fasting plasma
metabolomics patterns following the exercise and weight loss
intervention. A secondary aim (OGTT metabolomics) was
initiated after the first two enrolled subjects (a completer and a
non-completer in terms of the entire weight loss/fitness interven-
Metabolic Health and the Systemic Metabolome
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tion) finished Test Week 1. Thus, Test Week 1 OGTT
metabolomics were only available for 13 subjects. After an
overnight fast, during Day 3 or 4 of the Test Week period,
participants reported to the WHNRC at which time most women
had a catheter placed in an antecubital vein (others for which
catheterization was difficult had samples collected by venipuncture
during the OGTT). Approximately 15–30 min. later, a standard
75 g glucose OGTT was administered. EDTA-treated blood
samples were taken prior to the glucose drink (‘‘overnight fasted’’)
and at 30, 60, 90, and 120 minutes after ingestion. Plasma glucose
was determined at the UCDMC using a Beckman Coulter clinical
analyzer DXC800, and serum insulin was analyzed using standard
methods as per manufacturer’s protocols (ADVIA Centaur,
Siemans). The insulin sensitivity index (‘‘Matsuda index’’) was
calculated per Matsuda and DeFronzo [22]. HbA1c was measured
by UCDMC using a Trinity Biotech Ultra 2 HbA1c Analyzer.
Weight Loss and Fitness Regimen
Subjects were prescribed a self-selected calorie-restricted diet
based on the DGs and using the DRI equation to target a 10%
body mass loss over 14 weeks (ca. 500–600 kcal/day reduction). A
Baecke physical activity questionnaire [23] was administered to
assess self-reported physical activity level with a score of 5 for the
lowest activity and 15 for the highest activity related to work,
sport/exercise, and non-sport leisure categories; we used a score of
7 for calculating maintenance calories. Participants recorded daily
food intake in diaries and received weekly counseling from a
registered dietitian. Subjects were provided with a daily nutritional
supplement (Bayer One-a-Day for Women) during the interven-
tion to assure adequate intake of essential vitamins and minerals.
Body mass was measured weekly on an electronic scale (Scale-
Tronic model 6002; Wheaton, IL) to the nearest 0.1 kg with
participants in light clothing, all jewelry removed, pockets
emptied, and without shoes. Height was measured to the nearest
0.1 cm using a wall-mounted stadiometer (Ayrton Stadiometer
model S100; Prior Lake, MN), and body mass index (BMI, kg/m2)
calculated. Body fat mass and fat-free mass were measured by dual
energy X-ray absorptiometry (DEXA, GE Lunar Prodigy Encore
v10.5, Madison, WI). During Test Week 1, a graded cycle
ergometer test (SRM ergometer, Colorado Springs, CO) was
preformed to determine peak oxygen consumption (VO2peak).
Participants arrived at the UC Davis Sports Medicine Clinic after
consuming a standard breakfast (Menu 2) 2–3 hours prior to
exercise. During Test Week 1, the participants received a resting
ECG, a spirometry test, and a medical clearance exam by a Sports
Medicine Clinic physician. For the exercise test, participants
completed a 5 min warm up, followed by a graded exercise test to
exhaustion (initial workload of 50 W, increased by 20 W every
2 min until volitional fatigue). A metabolic cart (Parvo Medics
TrueOne 2400, Sandy, UT) was used to take continuous indirect
calorimetry measurements. At the end of every 2-min stage, the
following data were recorded: HR, blood pressure (BP) by
auscultation, and rating of perceived exertion (RPE) using a 0–
10 scale [24]. VO2peak was determined as the highest VO2 (ml/
kg/min) over a 30 s period. The VO2peak measurement was
replicated during Test Week 2.
Total length of time for the weight loss and fitness intervention
phase of the study varied from 14–17 wk, necessitated to match
Test Weeks with respect to menstrual phase within each subject to
avoid any potential cycle-associated changes in glucose and insulin
homeostasis [25,26] or metabolomics outcomes. If a follicular
phase (by self-report of menses) could not be achieved for an
individual for Test Week 1, that individual’s Test Week 2 was
targeted to coincide with the same reported menstrual phase they
were in for Test Week 1. Serum luteinizing hormone (LH) and
follicle stimulating hormone (FSH) were analyzed at UCDMC
(Siemens ADVIA Centaur chemiluminometric immunoassay) to
evaluate cycle stage post hoc.
Participants engaged in a prescribed exercise regimen a
minimum of 4 times/wk for the duration of the intervention as
directed by WHNRC Physiology Support Lab (PSL) exercise
physiologists. Over the first 4 intervention weeks, participants
exercised aerobically 4 days/wk for 30 minutes each (treadmill or
cycle ergometer) at an intensity of 60–70% of their maximal HR as
determined in the VO2peak test. During intervention weeks 5–8,
exercise sessions were increased to 40 minutes/session, 4 days/wk
and during intervention weeks 9 onward the intensity was
increased to a HR of 75% of maximal. Participants wore HR
monitors during all exercise sessions to ensure that they were
exercising at the appropriate intensity for the prescribed amount of
time, with digital information downloaded by PSL staff weekly to
ensure compliance.
Metabolite Analysis
The details of sample handling, metabolite detection and
analysis have been presented in detail elsewhere [8,27]. In brief,
EDTA plasma aliquots (15 mL) were extracted and a set of 13 C8–
C30 fatty acid methyl ester internal standards were added,
followed by methoximation/trimethylsilylation derivitization with
10 mL methoxyamine hydrochloride in pyridine followed by
90 mL MSTFA. Analytes in a 0.5 mL sample injection were
separated using an Agilent 6890 gas chromatograph (Santa Clara,
CA) equipped with a 30 m60.25 mm i.d., Rtx5Sil-MS column
with 0.25 mm 5% diphenyl film and a 10 m integrated guard
column (Restek, Bellefonte PA). Chromatography was performed
with constant flow of 1 mL/min while ramping the oven
temperature from 50uC to 330uC with 22 min total run time.
Mass spectra were acquired on a Leco Pegasus IV time of flight
mass spectrometer (St. Joseph, MI) with a 280uC transfer line, a
250uC ion source, and 270eV electron ionization impact. Mass
spectra were acquired from m/z 85–500 at 17 spectra s21 and
1850 V detector voltage. Result files were exported to servers and
processed by the Fiehn lab metabolomics BinBase database.
Database entries in BinBase were matched against the Fiehn mass
spectral library of 1,200 authentic metabolite spectra using
retention index and mass spectrum information or the NIST05
commercial library. Identified metabolites were reported if present
in at least 50% of the samples. Peak heights of quantifier ions for
each reported metabolite were normalized to the sum intensities of
all reported metabolites and these relative abundances were used
for statistical investigation. External 5-point calibration curves
established with mixtures of 30 metabolites allowed for the routine
assessment of instrument sensitivity and analyte intensity with
respect to the instrument dynamic range. Each chromatogram was
further controlled with respect to the total number of identified
metabolites and total peak intensities to ensure that outliers did not
confound the statistical analysis.
Statistical Analysis & Modeling
Linear mixed effects models. Models were used to identify
significant intervention-associated changes in fasting and AUC
metabolite values. Variables were transformed to normality, as
evaluated by the Anderson Darling test for normality, using
variable-wise log and power transformations, implemented in the
R statistical language v2.15.1 [28]. Mixed effects models, treating
the intervention (pre- vs. post-) as the main effect and individual
subjects as random effects, were constructed on transformed
variables using the MIXED procedure in SAS for Windows
Metabolic Health and the Systemic Metabolome
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Release 9.3 (Cary, NC). A false discovery rate associated with the
multiple hypotheses testing was adjusted to allow for a maximum
5% probability (q = 0.05) of false positives [29]. Fasting and
analyte AUC changes with intervention were also compared using
paired t-test with subject data from completers for which data were
available from both Test Week 1 and Test Week 2, and
conclusions drawn did not differ from the mixed model approach
that included all participants; thus, the latter is reported herein.
Using the group differences and variance in the concentration of
the plasma metabolite 2-HB derived from our prior studies in
obese women [8], and assuming an 80% power to detect a mean
group difference equal to the SD, a power calculation indicated
that our study design of 12 completing subjects was acceptable.
Partial least squares discriminant analysis. PLS-DA was
implemented in imDEV 1.4.2 [30] and R, package pls [31]. PLS-
DA modeling was used to identify optimal metabolic fasting and
AUC classifiers between pre- or post-intervention conditions. An
independent PLS model was developed on intervention adjusted
data to identify metabolic changes correlated with time during the
OGTT. Models were calculated using autoscaled data, leave-one-
out cross-validation and their parameters used to identify
intervention-associated and OGTT-responsive multivariate meta-
bolic effects. A PLS-DA model (‘‘combined model’’) was also
constructed using factors derived from the overnight-fasted model
and the OGTT-AUC model. Metabolites were retained if their
model weights differed significantly from the mean parameter
weight at p,0.05 using a one-sample t-Test. Positive and negative
coefficients were tested separately. Permutation tests (n = 100)
were used to compare the optimized (n = 48) and all parameter
(n = 648) models’ performance statistics to their respective random
NULL distributions. Distributions for the model cross-validated fit
on training data (Q2), root mean squared error of prediction on
test data (RMSEP), and area under the receiver operator
characteristic curve (AUROC) (n= 100) by randomly splitting
the samples between (2/3) training and (1/3) test sets. Statistical
distributions for permuted models’ performance measures were
calculated using identical procedures, in addition to permutation
of the dependent variable or samples pre- or post-intervention
assignment.
OGTT-responsive metabolic chemical similarity
network. A chemical similarity network was used to map and
visualize OGTT-associated changes in metabolite levels within a
biological context. In this network, vertices represent metabolites
that are connected by edges (lines) based on chemical similarity
(Tanimoto similarity .0.7) calculated in R using the package
ChemmineR [32]. In this network vertex size is used to encode the
absolute value of the PLS-DA latent variable 1 (LV1) model
loading (importance/magnitude of metabolic change during the
OGTT) and vertex color the sign of the LV 1 loading or direction
of metabolic change during the OGTT (decrease, blue; increase,
red).
Results
Body Mass loss and improvements in metabolic health
indices following a fitness and dieting intervention
Of the 55 overweight to obese sedentary women initially
screened using clinical blood lab results, 18 (36%) presented with
insulin resistance as defined by our criteria (Figure S1). Figure 1
highlights the successful body mass maintenance achieved in Test
Weeks 1 and 2 that preceded and followed, respectively, the
weight loss intervention phase. Results for body mass, body fat,
insulin resistance indices, and other phenotype variables for the 15
compliant subjects enrolled in the study are provided in Table 1.
As expected, there was a significant reduction in body mass and
body fat during the intervention, and markedly improved insulin
sensitivity as indicated by increased Matsuda index. Although
there is no consensus Matsuda index (a.k.a. ‘‘Composite Index’’)
indicative of insulin resistance or diabetic risk, a value of ,2.5 has
been used to identify insulin-resistant subjects in a cross-sectional
cohort of normal glucose tolerant adults (representing the lowest
,20–33% of insulin sensitivity in the population; Ref. [33]).
Similarly, obese subjects considered ‘‘at risk’’ for metabolic disease
had a Matsuda index ,2.5 [34,35]. Fitness was significantly
increased by intervention as indicated by higher VO2peak and
increased maximal work on a cycle ergometer (Table 1).
Directional changes in fitness and glucose sensitivity parameters
were the same even if just examining the subset of 12 women
completing both Test Week 1 and Test Week 2 (File S2:
Supplemental Materials 2). There were no significant differences
in pre- vs. post-intervention serum FSH or LH concentrations in
subjects completing both Tests Weeks in the protocol and neither
hormone was correlated with QUICKI or the Matsuda index at
either time point (data not shown). As anticipated, FSH and LH
concentrations were tightly correlated (e.g., r = 0.816 and r = 0.705
in Test Weeks 1 and 2, respectively, p#0.01).
OGTT-associated changes in plasma metabolites
Application of PLS-DA modeling using all identified metabo-
lites (named with PubChem Compound Identifier [CID]) enabled
discrimination of time-associated metabolic phenotypes in subjects
as illustrated in Figure 2. A clear left-to-right shift along the X
axis (latent variable dimension 1, LV1) was evident for all subjects,
indicating a metabolic trajectory common to all subjects following
the OGTT. Covariate adjustment for the effect of the weight loss
and fitness intervention, done prior to modeling, enabled
visualization of post-OGTT-associated time course metabolite
patterns that were shared in both the pre-intervention and post-
intervention states. Put differently, OGTT impacted general
Figure 1. Study schematic and weight loss patterns in obese,
sedentary women undergoing a fitness and weight loss
intervention to assess changes in the plasma metabolome.
Blood was drawn in the overnight-fasted and post-OGTT conditions,
during each of pre-intervention and post-intervention Test Weeks
identically controlled for dietary intake, weight maintenance, and
physical activity. To match menstrual cycle stage within individuals, Test
Week 2 was after an intervention period ranging from 14-17 weeks (14
week time point mean is depicted for clarity). Of 15 women completing
Test Week 1, 12 remained throughout the study to finish Test Week 2.
doi:10.1371/journal.pone.0084260.g001
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metabolite patterns in a qualitatively similar way under both pre-
and post-intervention conditions for the majority of metabolites.
Variance in plasma metabolite levels did not discriminate the 90
and 120 min post-OGTT time points (see overlapping ovals)
indicating that the most dynamic metabolite changes took place
between 0–90 min.
To gain insight into OGTT-associated trends in broad classes of
plasma metabolites, a chemical similarity network of identified
metabolites was constructed using data from both the pre- and
post-intervention phases and all OGTT time points (Figure 3).
From this map, it is clear that the OGTT triggered the following
general shifts in blood.
Lipid Metabolism. A reduction in most lipid class members
was observed, including free fatty acids, glycerol, and 3-
hydroxybutyrate (b-hydroxybutyrate). This is consistent with an
expected reductions in lipolysis and ketogenesis following the post-
OGTT insulin surge. Medium-chain length dicarboxylic acids
adipic (di-C6) and azaelic (di-C9), and medium-chain fatty acids
caprylic (C8:0) and pelargonic (C9:0) were decreased in plasma
with the OGTT, likely due to reductions in peroxisomal v-
oxidation and b-oxidation. A suite of very long chain fatty acids
(arachidic [C20:0], behenic [C22:0], lignoceric [C24:0], cerotic
[C26:0], montanic [C28:0]) displayed mixed patterns of plasma
concentrations post-OGTT, depending upon intervention phase.
In the pre-intervention phase, post-OGTT plasma concentrations
of these VLCFAs were stable or fell whereas levels tended to rise in
the post-intervention phase (see results below). These results
suggest that intervention led to alterations saturated long-chain
fatty acid (LCFA) elongation in the course of the OGTT.
Amino Acid Metabolism. With OGTT there was a decrease
in plasma amino acid concentrations, with a concurrent increase
in several measured downstream catabolism products, e.g.
cysteine-cystine (Met derivatives), 2-HB (Met or Thr derivative),
2-ketoisocaproic acid (Leu metabolite), kynurenine and 5-methox-
ytryptamine (Trp products). These patterns are consistent with an
effect of insulin to promote amino acid uptake and tissue
utilization.
Carbohydrate Metabolism. As expected, there were
OGTT-associated increases in glucose and glucose-derived
metabolites, e.g. glucose-1-phosphate, fructose, lactate, pyruvate,
UDP-glucuronic acid (UDP-glucose derivative) and a rise in
organic acids including TCA cycle intermediates. This highlights
the anticipated rise in glucose oxidative catabolism and increased
engagement of minor pathways of glucose conversion (e.g., to
fructose via the sorbitol pathway).
Splanchnic Metabolites. We observed a modest decrease in
cholesterol and the cholesterol precursor lathosterol with the
OGTT. In addition, in the post-intervention phase the OGTT
elicited an increase in plasma gut microbial metabolite propane-
1,2,3-tricarboxylate (a.k.a. tricarballylic acid; discussed in more
detail below).
Figure 3 also illustrates post-OGTT increases in plasma
concentrations of several adulterants we subsequently identified in
the commercial OGTT solutions. For instance, there was a large
increase in levoglucosan, a molecule produced upon heating of
carbohydrates including glucose. There was no levoglucosan
detected following injection of a derivatized pure glucose standard
into the GC-TOF instrument (data not shown), indicating that this
molecule was not a by-product of the heating step of sample
analysis. However, levoglucosan was readily detected in post-hoc
analyses of all OGTT solutions, likely present due to heating of the
dextrose syrup ingredient that occurs prior to compounding of the
OGTT drinks. Post-OGTT increases in plasma 5-hydroxymethyl-
furfural (5-HMF) derivatives (5-hydroxymethyl-2-furoic acid
[HMFA] and the HMFA metabolite 2,5-furandicarboxylic acid
[FDCA]) were also detected. 5-HMF was detected in all of the
OGTT solutions and is a molecule commonly found in heat-
processed foods, emanating from dehydration of sugars. However,
FDCA was not detected and HMFA was only observed in one of
the OGTT solutions. The explanation for the relatively large
increase in plasma HMFA and FDCA post-OGTT (Figure 3) is
Table 1. Body mass, fitness, and glucose homeostasis indices in previously sedentary obese women following a weight loss and
fitness intervention.
Pre-interventiona Post-interventionb p-value Mixed Modelc
Age 40.465.2 (median, 38.8) – –
Body Mass (kg) 88.662.1 83.063.1 ,0.0001
BMI, kg/m2 33.560.6 31.060.9 0.0007
Body Fat% 47.561.0 43.461.5 ,0.0001
Fat Mass (kg) 41.961.6 36.262.4 0.0001
Fat Free Mass (FFM, kg) 43.160.8 43.360.9 NS
VO2peak (mL/kg/min) 21.161.1 25.661.1 ,0.0001
VO2peak (mL/kg FFM/min) 43.761.6 49.461.4 ,0.0001
Maximal Power (Watts at VO2peak) 142.063.8 166.766.4 ,0.0001
Fasting Glucose (mg/dL) 89.161.5 84.661.5 0.0159
Fasting Insulin (mU/mL) 18.562.1 13.761.7 0.0092
Matsuda Index 1.9760.17 2.9160.36 0.0076
QUICKI 0.31560.004 0.33260.006 0.0046
apre-diet and exercise intervention, n = 15 (self-reported ethnicity, n: White, 9; Hispanic, 3; Black, 1; Asian, 1; Other, 1).
bpost-diet and exercise intervention, n = 12.
ccomparisons using paired t-tests from subjects completing both Test Week 1 (pre-intervention) and Test Week 2 (post-intervention) yielded identical statistical
patterns.
Values are means 6 SEM; NS = not statistically significant.
doi:10.1371/journal.pone.0084260.t001
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likely that these metabolites represent terminal products of 5-
HMF, a molecule rapidly and completely metabolized (endoge-
nous and microbial) following ingestion [36–39]. Notably,
tricarballylic acid was not detected in the OGTT solutions,
indicating it was not an adulterant of these preparations.
Plasma metabolites altered in the overnight-fasted state
by the fitness and weight loss regimen
We next sought to identify metabolites with systemic concen-
trations impacted by weight loss, improved insulin sensitivity and
fitness (defined here as ‘‘metabolic health’’). Metabolites with
significant concentration changes comparing the overnight-fasted
pre- and post-intervention states are presented in Table 2. The
list includes equal numbers of known and as-yet unidentified
metabolites and represents just 5.6% of all metabolites detected.
Thus, the weight loss and fitness regimen resulted in only modest
alterations in overnight-fasted concentrations in the metabolite
classes detected by this analytical platform. Some trends observed
from these overnight-fasted plasma metabolite data include: (1)
Modest but statistically significant increases in the 5-HMF
derivatives HMFA and FDCA, as well as a modest but significant
decrease in food-derived 1,5-anhydroglucitol. Thus, even in the
overnight-fasted state and under highly-controlled dietary condi-
tions, there were subtle intervention-associated shifts in levels of
blood metabolites that originate from diet and microbial
metabolism. (2) A 40% reduction in the concentration of the
low-abundance metabolite a-ketoglutarate, ,32% lower level of
the glutamate derivative gamma-aminobutyric acid (GABA), and
significantly reduced pyruvic acid and uric acid. (3) A ,30%
reduced concentration of behenic (C22:0) fatty acid. Concentra-
tions and pre- vs. post-intervention comparisons for all detected
metabolites are provided in Table S1.
Plasma metabolites with post-OGTT concentration
excursions (AUCs) altered by the fitness and weight loss
regimen
Post-OGTT plasma AUCs of 95 metabolites differed signifi-
cantly from zero at one or both intervention time points (one-
sample t-test, p,0.05; equivalent to 95% confidence interval not
overlapping with zero) (Table S2). Some metabolite AUCs were
significantly different from zero in both pre- and post-intervention
(38 metabolites), whereas changes in others were significantly
altered by the OGTT only in the pre- (14 metabolites) or only in
the post-intervention (43 metabolites) phases. Of these metabolites,
11 displayed statistically-significant differences comparing the pre-
vs. post-intervention phases (Table 3). The glucose AUC was
reduced following the intervention (File S2: Supplemental
Materials 2, first metabolite AUC panel in series) but this did
not reach statistical significance (p= 0.06). From this analysis, it is
clear that the OGTT challenge successfully unmasked metabolic
health-associated patterns that were not detected using fasting
metabolite comparisons alone. Excursion plots of the Table 3
metabolites are depicted in Figure 4. From this figure it is clear
that the AUC of a-ketoglutarate was significantly enhanced
following the fitness and weight loss intervention, partly explained
by a significantly lower time zero (overnight-fasted) concentration.
Other unique patterns illustrated in Figure 4 included an
unexpected post-intervention rise in AUCs for arichidic acid
(C20:0) and the gut microbe-derived propane-1,2,3-tricarboxylate
Figure 2. Subject Scores Plot derived from a partial least squares discriminate analysis (PLS-DA) model using temporal variance in
identified plasma metabolites over the course of an OGTT in women. Each time point is represented by a different colored oval surrounding
subject-time point groupings (see legend), and the score of each subject is represented as a symbol within time point cluster. Both pre- and post-
intervention data were used to generate this plot (see Results). Note that variation in metabolite levels at each of the time points led to separation
(discrimination) of clusters from one another, with the exception of the final 2 time points for which subject scores were similar.
doi:10.1371/journal.pone.0084260.g002
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(tricarballylic acid). Arachidic acid is derived from Elongation of
very long chain fatty acids (Elovl) enzyme activity using stearic acid
(C18:0) as substrate, and differential pre- and post-intervention
AUC shifts patterns of other VLCFA Elovl products were
qualitatively similar to arachidic (Figure 5). All detected
metabolites’ AUCs are provided in Table S2, and graphs for all
metabolites’ post-OGTT excursions are provided in File S2
(Supplemental Materials 2).
PLS-DA Model using overnight-fasted metabolite levels
and post-OGTT AUCs to identify the most robust factors
discriminating the pre- vs. post- fitness and weight loss
intervention phenotypes
To determine the best combination of metabolic parameters
indicative of an improvement in metabolic health, a combined
model was generated that utilized fasting metabolite levels, AUCs,
and clinical indices of insulin sensitivity (Matsuda index, QUICKI,
fasted insulin and glucose). First, to build this combined PLS-DA
model, feature selection was used to optimize fasting metabolites
that best differentiate pre- and post-diet and fitness intervention
(Table 4, 1st column). Features were selected based on a filter
approach [40] on variable coefficient weights [41](see Methods).
PLS scores based on a model constructed from discriminating
overnight-fasting analyte variables reasonably separated pre- and
post-intervention subject groups as shown in the subject scores plot
in Figure 6A. Second, AUCs for all analytes were similarly
modeled, and feature selection was used to optimize independent
AUC values (Table 4, 2nd column) that best differentiated pre-
and post-diet and fitness intervention phenotypes, as illustrated in
the subject scores plot in Figure 6B.
Finally, a combined model utilized both fasting and post-
OGTT AUC parameters to identify all factors that discriminate
the subjects based on pre- and post-intervention status (Table 4).
Figure 7A depicts the PLS-DA subject scores plot output from
this model showing separation of groups using this approach, and
Figure 7B is a loadings plot indicating the most important
features that best defined the pre- vs. post-intervention metabolic
Figure 3. A chemical similarity network of identified metabolites was used to visualize OGTT-associated changes in metabolite
levels following an OGTT in women. Vertices represent metabolites that are connected by edges (lines) based on chemical similarity (Tanimoto
similarity .0.7). Loadings on the first latent variable in the PLS model for metabolic changes correlated with time during the OGTT are mapped to
vertex size (absolute loading) and color is used to display the direction of the change (sign of loading: red, increase; blue, decrease; gray, unclear
change or differential change in pre- vs. post-intervention conditions).
doi:10.1371/journal.pone.0084260.g003
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phenotype differences. These results indicate that improved
metabolic health was defined by a subset of metabolites, including
(as examples): (1) Changes in the AUC and/or fasting plasma
levels of diet or gut microbe-derived molecules such as stigmas-
terol, propane-1,2,3-tricarboxylate (tricarballylic acid), furoic acid
derivatives, and c-tocopherol; (2) Shifts in plasma a-ketoglutarate,
UDP-glucuronic acid, malate and pyruvate suggestive of changes
in mitochondrial function and glucose oxidative and non-oxidative
metabolisms; (3) Alterations in AUC of oleamide, an endocanna-
binoid; (4) Reduction in post-OGTT purine and pyrimidine
metabolites uric acid and uridine.
Metabolite and phenotype correlations in the pre- and
post-intervention periods
An important aim of the current work was to identify
metabolites that correlate with insulin sensitivity and blood sugar
control. To this end, a Spearman’s cross-correlation plot (CCP) for
phenotype and metabolite variables was constructed to identify
factors that associate with one another in the pre- and post-
intervention phases (Tables S3 and S4). For clarity, this analysis
was only conducted with factors having PLS-DA loadings values.
+/21 SD from the mean loadings values. As expected, the
Matsuda insulin sensitivity index was strongly and negatively
correlated with fasting plasma insulin and the QUICKI score
(derived from fasting insulin and glucose), regardless of interven-
tion phase (Table 5). In addition, 8 and 10 metabolites,
respectively, were correlated with the Matsuda index in the pre-
and post-intervention phases (Table 5). Of note, the only factor
that correlated significantly in both phases was fasting plasma a-
ketoglutaric acid (a-KG), as this metabolite’s fasting plasma
concentration was inversely correlated with insulin sensitivity.
Xeno-metabolites directly or indirectly from diet also correlated
with Matsuda index: e.g., FDCA and c-tocopherol. Altogether,
these results and other correlation patterns in Tables S3 and S4
highlight that relationships between metabolite factors and insulin
sensitivity are malleable with changes in fitness, weight, or other
aspects that were altered by the study intervention.
Discussion
A better understanding of the systemic metabolite changes that
track insulin resistance and pre-diabetes could help lead to
development of new prognostic biomarkers, and will inform on the
basic physiological processes and tissue cross-talk events that are
associated with metabolic status. Comprehensive metabolite
profiling in the insulin-resistant and T2D states has highlighted
that in addition to compromised glucose homeostasis, these
conditions are associated with perturbations in fatty acid, amino
acid, and bile acid metabolism [2–16]. Most metabolomics studies
in this arena have focused on the overnight-fasted state or under
non-controlled dietary conditions, but metabolic phenotypes could
manifest more robustly under dynamic conditions that assess
metabolic flexibility rather than single static measures [17–21].
The current study assessed, for the first time, changes in post-
OGTT comprehensive metabolite patterns following a diet and
fitness intervention that markedly improved metabolic health
indices (weight loss, increased fitness, and improved insulin
sensitivity). The three major findings are outlined below.
Table 2. Overnight-fasted concentrations of identified and as-yet unidentified plasma metabolitesa that were significantly altered
by a weight loss and fitness intervention in adult women.
Pre-interventionb Post-interventionc Fold of Pre-intervention p-valued
5-hydroxymethyl-2-furoic acid (HMFA) 172621 200611 1.2 0.0409
glycine 181000611361 207000613856 1.1 0.0321
2,5-furandicarboxylic acid (FDCA) 153622 168612 1.1 0.0341
1,5-anhydroglucitol 11500068004 9480065196 0.83 0.0281
BB369638 1260683 1040684 0.83 0.0398
uric acid 8650065422 6950064619 0.80 0.0005
BB314770 1580061110 123006779 0.78 0.0435
BB225396 20406527 15806254 0.77 0.0230
BB402237 32106181 23806687 0.74 0.0045
c-tocopherol 21106219 15406254 0.73 0.0196
behenic acid 14706207 1060695 0.72 0.0407
BB226851 12606139 9126104 0.72 0.0054
BB288808 7276300 518638 0.71 0.0372
GABA 51806620 35206520 0.68 0.0143
pyruvic acid 50406775 34006866 0.67 0.0458
BB223513 29906310 19706225 0.66 0.0012
BB228147 9476108 603658 0.64 0.0175
a-ketoglutaric acid 804688 480675 0.60 0.0010
BB206309 32800621430 76206808 0.23 0.0429
ametabolites detected by GC-TOF, values are in quantion peak heights; unidentified metabolites indicated with their BinBase (BB) nomenclatures; values are mean 6
SEM; values for glucose and insulin are provided in Table 1.
bpre-diet and exercise intervention, n = 15.
cpost-diet and exercise intervention, n = 12.
dp-value for a mixed effects linear model (*no comparison met the 5% significance criteria after false discovery rate correction at a q= 0.05).
doi:10.1371/journal.pone.0084260.t002
Metabolic Health and the Systemic Metabolome
PLOS ONE | www.plosone.org 8 January 2014 | Volume 9 | Issue 1 | e84260
First, we made the novel observation that intervention led to
alterations in circulating concentrations of gut-derived xeno-
metabolites both in the fasted state and during a glucose challenge,
suggesting that gut function and/or microbial metabolism were
responsive to host metabolic health status. That gastrointestinal
microbes generate gut and systemic short-chain fatty acids
(SCFAs) has been long-appreciated, but it is increasingly clear
from rodent and human models that many other microbe-derived
metabolites make their way into the bloodstream (e.g. [42–49]).
Current perspectives tend to emphasize the importance of the gut
microbiome on driving obesity and dysfunctional metabolism in
the host (reviewed in [50,51]). However, the degree to which host
insulin sensitivity, fitness, or adiposity impacts microbial ecology
and metabolism of gut-derived xeno-metabolites is not as well
established. Provision of oral glucose was associated with a
significant post-OGTT change in plasma concentration of the
citrate analog propane-1,2,3-tricarboxylate (tricarballylic acid), a
pattern altered following the weight loss and fitness regimen.
Tricarballylic acid is a product of gut microbial metabolism of
food-derived trans-aconitate (or to a smaller degree cis-aconitate,
citrate or isocitrate from host or diet), classically described in
ruminants [52,53]. Rat cecal bacteria, but not liver preparations,
have been shown to produce tricarballylic acid from aconitate, and
rat cecal bacteria showed no ability to degrade tricarballylic acid
[54]. Altogether, the results in rats indicate that tricarballylic acid
is a terminal xeno-metabolite made by mammalian gut microbes.
Supporting a microbial origin of tricarballylic acid was the
observation that its AUC displayed a strong inverse correlation
with fasting plasma concentration of 2,3,5-trihydroxypyrazine
(r =20.643; p = 0.02 [pre] and r =20.895; p,0.0001 [post]), a
metabolite that has not been reported to be synthesized by
mammals and is structurally related to plant- or pathogen-derived
hydroxypyrazine metabolites. Thus, we speculate that fasting
plasma 2,3,5-trihydroxypyrazine concentrations marked preva-
lence or metabolic activity of specific gut microbes that are
associated with tricarballylic acid production. In addition to
aconitate as precursor, we cannot exclude the possibility that
microbes utilized the citrate additive contained in the OGTT
solutions to produce tricarballylic acid. The mechanisms under-
lying the shift in tricarballylic acid post-OGTT plasma excursion
upon improvement in metabolic health remain to be evaluated
experimentally, but changes in gut tricarballylic acid production
Figure 4. Post-OGTT excursions in plasma concentrations of metabolites that displayed a significant difference in area-under-the-
curve (AUC) when comparing the pre- and post-intervention phases (red and green lines, respectively) of a weight loss and fitness
regimen in women. Values are quantion peak heights for each of the individual metabolites.
doi:10.1371/journal.pone.0084260.g004
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concomitant with altered microbial ecology may have occurred.
Tricarballylic acid uptake transporters in the gut brush border,
described as a Na+-dependent transporter shared with citrate,
have been described for cattle [55] and likely played a role in
glucose-responsive uptake of this organic acid in our human
cohort. It remains to be seen if changes in blood levels of
tricarballylic acid impact human host biology, but in an extreme
example, rumen over-production of tricarballylic acid in cattle
eating grasses high in trans-aconitate is implicated in inhibition of
host tissue aconitase thought to contribute to grass tetany [52,53].
Figure 5. Post-OGTT excursions in plasma concentrations of very long chain fatty acid (VLCFA) metabolites that are products of the
Elongation of very long chain fatty acid (Elovl) enzymes. Illustrated are temporal changes in metabolites when comparing the pre- and post-
intervention phases (red and green lines, respectively) of a weight loss and fitness regimen in women. Values are quantion peak heights for each of
the individual metabolites. Also shown is the set of reactions catalyzed by ELOVL including metabolites detected in this study.
doi:10.1371/journal.pone.0084260.g005
Table 3. Post-OGTT excursions (AUC) of plasma identified and as-yet unidentified metabolitesa and serum insulin significantly
changed by a weight loss and fitness intervention in adult women.
Pre-interventionb Post-interventionc p-valued AUC change
insulin {1640061969 {1330062165 0.0006 Q
UDP-glucuronic acid {599000652696 {426000643301 0.0006 Q
levoglucosan {121000611926 {90000613279 0.0049 Q
BB199794 {11200006141449 {7930006106810 0.0478 Q
histidine 9020006554700 {25160006207846 0.0342 Q
a-ketoglutaric acid {1920067488 {46500610681 0.0456 q
arachidic acid 284800663790 {102000643301 0.0088 q
propane-1,2,3-tricarboxylate
(tricarballylic acid)
231400627735 {62600620207 0.0179 q
BB235972 232500619414 {35200615877 0.0197 q
BB226848 2490006188598 {3980006106810 0.0262 q
BB226842 29140006748845 {13300006433012 0.0447 q
ametabolites measured by GC-TOF, AUC values are derived from quantion peak heights; unidentified metabolites indicated with their BinBase (BB) nomenclatures;
values are mean 6 SEM.
bpre-diet and exercise intervention, n = 13.
cpost-diet and exercise intervention, n = 12.
dp-value for a mixed effects linear model (no comparison met the 5% significance criteria after false discovery rate correction at a q = 0.05).
{AUC significantly different from zero; not shown are metabolite AUCs that were significantly different by intervention period but that were not different from zero at
either time point due to high variance (see Results).
doi:10.1371/journal.pone.0084260.t003
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Figure 6. Subject Scores Plots derived from PLS-DA models using either overnight-fasted or post-OGTT (area-under-the-curve,
AUC) metabolite variances, illustrating that differences in select metabolic features successfully discriminate subjects based on
intervention phase. Each symbol represents the score for a single subject during the pre- or post-intervention phases (red and green, respectively).
For both models, the best discrimination of phases was evident along the latent variable 1 axis (LV1). Note that one subject’s score from the post-
intervention phase overlapped with the scores cluster of the pre-intervention subjects, indicating similarity in fasted metabolite pattern with pre-
intervention phase women (also see Results).
doi:10.1371/journal.pone.0084260.g006
Table 4. Plasma metabolite and endocrine parameters used to generate a combined PLS-DA model that best discriminates the
pre- and post- weight loss and fitness intervention states in adult women.
Parameters found in the overnight-
fasted PLS-DA modela
Parameters found in the AUC PLS-DA
modelb
Parameters found in both fasting &
AUC modelsc
Factors added back for final
combined modeld
malic acid arachidic acid 213961 oleamide AUC
288808 oleamide 281268 226851
228147 propane-1,2,3-tricarboxylate (tricarballylic
acid)
a-ketoglutaric acid HMFA
uridine 235972 c-tocopherol insulin
223513 295002 cystine serine
402237 threonic acid uric acid glucose (clinical)
insulin glutamine 211972
217893 UDP-glucuronic acid N-methylalanine
glycine stigmasterol
lactic acid *levoglucosan
5-hydroxymethyl-2-furoic acid (HMFA) 226848
serine
226851
arginine/ornithine
glutamic acid
pyruvic acid
glucose (clinical)
aParameters selected in the overnight-fasted plasma metabolite PLS-DA model.
bParameters selected in the post-OGTT plasma metabolite AUC PLS-DA model.
cParameters observed in both the overnight-fasted metabolite PLS-DA model and the AUC-only PLS-DA model.
dParameters not found initially in the combined model, but added back because of their presence in either the the overnight-fasted metabolite PLS-DA model or AUC-
only model.
*adulterant in OGTT solution (see Results).
doi:10.1371/journal.pone.0084260.t004
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However, results were equivocal in rat liver slices treated with
tricarballylic acid at a concentration of as-yet unknown physio-
logical relevance [54]. Microbial transformation of aconitate to
tricarballylic acid strongly modified short-chain fatty acid (SCFA)
production in artificial cultures [52], suggestive of another means
by which host physiology could be impacted by changes in
accumulation of this metabolite or the activities of its microbial
producers.
Other examples of blood xeno-metabolites altered by the weight
loss and fitness intervention included increased post-OGTT AUCs
for c-tocopherol and stigmasterol, and modest increases in fasting
concentrations of FDCA and 5-HMFA, the terminal metabolites
of the food-derived 5-HMF [36–39]. Also notable were interven-
tion-associated reductions in fasting plasma c-tocopherol and 1,5-
anhydroglucitol. Recently, in an epidemiology study assessing
environmental and dietary factors that increase the odds of
developing T2D, fasting blood c-tocopherol was one of the
strongest and most consistent risk factors, although the reason for
this observation is unknown [56]. In light of this, we propose that
circulating c-tocopherol in part reflects changes in gut biology that
are influenced by metabolic health. With respect to the food-
derived 1,5-anhydroglucitol, this metabolite fluctuates inversely
with large increases in glucose concentration or with diet [57], yet
these parameters were essentially stable when comparing the pre-
and post-intervention phases herein. Since a highly-controlled
feeding paradigm ensured that subjects in the current study ate
identical foods during the pre- and post-intervention testing weeks,
changes in tricarballylic acid and other xeno-metabolites may
reflect innate shifts in the subjects’ gut microbe ecology and host
metabolism/uptake of gut-derived metabolites. Gut permeability is
increased by high fat feeding, Metabolic Syndrome, obesity and
diabetes in humans, and these conditions are often associated with
an altered gut microbiome (reviewed in [50,51]). Consistent with
our perspective that host metabolic health can regulate xeno-
metabolite exposure, Zhao et al. reported that hippuric acid,
methylxanthine, methyluric acid, and 3-hydroxyhippuric acid
were reduced in urine of impaired glucose tolerant (IGT) subjects
[7]. In retrospect, we have also previously observed alterations in
fasting plasma levels of putative xeno-metabolites or co-metabo-
lites (those involving both host and microbial processing) in obese
T2D compared to weight-matched non-diabetic African-Ameri-
can women (e.g., 3,6-anhydrogalactose, benzoic acid, benzylalco-
hol, cis-3,4-methylene-nonanoylcarnitine, cis-3,4-methylene-hep-
tanoylcarnitine)[3,8]. Thus, a major implication of our findings
and those of Zhao et al. [7] is that changes in the host’s metabolic
health (insulin sensitivity, fitness, or adiposity) significantly
regulates meal-associated (transient) and fasting (chronic) systemic
exposure to xeno-metabolites.
Figure 7. Subject Scores Plot (A) and Variable Loadings Plot (B) derived from a combined PLS-DA model using both overnight-
fasted and post-OGTT (area-under-the-curve, AUC) metabolite variances. The model was calculated using a combination of the most
robust metabolic features included in separate PLS-DA modeling of the fasted and post-OGTT states (Table 4). Each symbol in the Scores Plot
represents the score for a single subject during the pre- or post-intervention phases (red and green, respectively). The best discrimination of phases
was evident along the latent variable 1 axis (LV1), and the contribution of individual metabolic phenotype factor variance toward separation of the
groups along LV1 is depicted in the Loadings Plot.
doi:10.1371/journal.pone.0084260.g007
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A second major finding was that weight loss and fitness
intervention increased post-OGTT plasma indices of saturated
very long chain fatty acid (VLCFA) elongation, with adipose tissue
ELOVL enzyme activity as a likely contributor. To our
knowledge, such a pattern has not been described previously.
The OGTT elicited an expected drop in the plasma concentration
of a variety of LCFAs, including ELOVL substrate stearic acid and
some VLCFAs, consistent with repression of lipolysis and
promotion of net tissue fatty acid uptake in response to insulin.
Unexpectedly, following intervention the post-OGTT plasma
excursions of VLCFAs were generally increased, especially
apparent for arachidic acid (C20:0), suggesting that saturated
fatty acid elongation was enhanced in response to insulin and
glucose. Products of the ELOVL 1 and 3 enzyme reactions include
the saturated VLCFAs found to be changed in the current study
[58], making these enzymes potential candidates underlying the
phenotype. One hint regarding a site of elongation of saturated
VLCFA post-OGTT emerged from correlation analysis: Plasma
arachidic acid AUC (and, to an extent, that of its downstream
ELOVL product behenic acid) was strongly correlated with body
fat (pre- and post-intervention r values $0.7, p#0.01; Tables
S3–S4). This points to adipose tissue as the likely site of fatty acid
elongation to generate arachidic and behenic acids following
OGTT in humans, and suggests that improved metabolic health
enhances these pathways. This speculation will, of course, require
experimental assessment. One possible explanation is that
improved insulin sensitivity promoted adipose tissue glucose
uptake, de novo fatty acid synthesis, and fatty acid sequestration
(reduced lipolysis) thus promoting ELOVL substrate availability
during the OGTT. Alternatively, it is worth considering that
training/fitness-derived signals could have increased adipose
ELOVL(s) expression: the Spiegelman lab recently described that
a potential training-induced myokine, FNDC5 or irisin, can
strongly trigger cultured murine adipocyte gene expression of
ELOVL3 (a.k.a. Cig30, a classic marker of activated brown
adipocytes) [59].
A third important finding was that the post-weight loss and
fitness intervention phenotype was marked by significant alter-
ations in blood organic acids, most notably a-ketoglutaric acid (a-
KG), malate, and pyruvate. One possible explanation is that
improved metabolic health altered mitochondrial function (e.g.,
anaplerotic/cataplerotic balance) and/or transamination reac-
tions. A novel finding was that fasting and post-OGTT plasma a-
KG concentrations were major discriminating variables when
comparing the pre-intervention phase (insulin-resistant, sedentary
obesity) and post-intervention phase (improved insulin sensitivity
and physical fitness). Fasting plasma a-KG was strongly and
inversely correlated with the Matsuda index, indicating that
improved insulin sensitivity reduced a-KG production and
transport to plasma, and/or increased a-KG clearance in the
basal state. One intriguing possibility is that fasting plasma a-KG
was reflective of improved post-intervention LCFA b-oxidation
efficiency and TCA cycle activity. Mitochondrial a-KG export
(cataplerosis) is coincident with high mitochondrial LCFA
availability accompanied by incomplete b-oxidation [60,61] and
at least for muscle, exercise interventions improve mitochondrial
oxidative capacity [62] and reduce incomplete LCFA b-oxidation
[63]. We observed increased fasting plasma malic acid (malate)
and decreased pyruvic acid (pyruvate) as discriminating variables
for the post-intervention phenotype, and post-intervention plasma
malic acid was inversely correlated with pyruvate (r =20.78,
p,0.01). Such a pattern is consistent with the idea that TCA cycle
capacity and more efficient glucose/pyruvate oxidation are
associated with improved metabolic health. Supportive of these
views was our observation that post-OGTT UDP-glucuronic acid
AUC was significantly reduced by the fitness and weight loss
intervention, suggestive of diminished non-oxidative metabolism of
glucose. Furthermore, following the weight loss and fitness
intervention, the post-OGTT a-KG excursion was significantly
increased, and post-OGTT AUC trajectories for other TCA
intermediates (e.g., isocitrate, fumarate, malate) also appeared
higher post-intervention (see File S2: Supplemental Materials 2).
Such results would be anticipated with greater post-OGTT
glucose carbon flux into the TCA cycle upon improvements of
insulin sensitivity and mitochondrial function, and may explain
why a higher glutamine excursion post-intervention was also a
discriminating factor in the PLS-DA model. Mitochondrial a-
KG/glutamate/glutamine are in equilibrium through bi-direc-
tional mitochondrial conversions [64,65]. Considering the central
role of a-KG in aminotransferase reactions or metabolite synthesis
(i.e., carnitine synthesis from butyrobetaine), we cannot exclude
that pre- vs. post-intervention patterns of this metabolite were
impacted by these routes. Notably, fasting glutamic acid (the
transaminase partner with a-KG) was also reduced following
intervention and was an important discriminating factor in the
PLS-DA model. Also, one cannot ignore the potential effect of gut
microbial metabolism of organic acids [48], which may have
impacted intervention-associated blood metabolites. These possi-
bilities will require experimental evaluation of organic acid kinetics
and microbial metabolism across a range of insulin sensitivities and
fitness levels. Regardless, our results indicate that measurement of
blood a-KG or its ratio with other discriminating variables could
be used to track insulin sensitivity and metabolic health status.
As a final point, we anticipated that improvements in insulin
resistance, weight loss and fitness would alter recently-described
metabolite biomarkers of insulin sensitivity and diabetes risk
including branched chain amino acids (BCAAs), phenylalanine,
tyrosine, and the methionine/threonine derivative 2-HB (reviewed
in [66]). However, in the current study plasma concentrations of
these amino acids, their derivatives, and their post-OGTT
Table 5. Correlations of interest between Matsuda insulin
sensitivity index and fasting plasma or post-OGTT metabolite
area-under-the-curve (AUC) in adult women either pre- or
post-weight loss and fitness intervention.a
Pre-interventionb Post-interventionc
insulin (20.872)*** insulin (20.804)**
QUICKI (0.923)*** QUICKI (0.839)***
a-ketoglutaric acid (20.549)* a-ketoglutaric acid (20.776)**
BB199777 AUC (20.654)* BB235972 (0.769)**
BB199794 AUC (20.560)* BB299159 (0.573)*
BB213961 AUC (0.560)* 2,5-furandicarboxylic acid (0.651)*
cystine AUC (0.599)* BB295002 AUC (0.811)*
c-tocopherol AUC (0.654)* BB299211 AUC (0.650)*
isolinoleic acid AUC (0.692)** levoglucosan AUC (20.720)**
salicylaldehyde AUC (0.637)* palmitoleic acid AUC (0.650)*
lysine (0.615)*
pyruvic acid (20.601)*
aContrasts and values are from Tables S3 and S4; Spearman’s correlation r
values are in parentheses; *p#0.05, **p,0.01, ***p,0.001.
bpre-diet and exercise intervention, n = 13.
cpost-diet and exercise intervention, n = 12.
doi:10.1371/journal.pone.0084260.t005
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reductions (AUCs) did not correlate with marked improvements of
insulin sensitivity. Similarly, in a small cross-sectional cohort,
Ramos-Roman et al. did not detect associations between post-
meal insulin sensitivity indices and patterns of BCAA-associated
carnitine derivatives [67]. In contrast, using multivariate analysis,
fasting blood BCAA or derivatives contributed to principal
components that correlated with insulin sensivity in a dieting trial
[68], although changes in BCAA were less apparent in a separate
study comparing against bariatric surgery weight loss [11]. In a
cross-sectional study comparing a large cohort with broader
differences in metabolic phenotypes, Shaham et al. demonstrated
that a higher fasting insulin concentration was associated with
blunted post-OGTT reductions in blood leucine/isoleucine,
suggestive of lower insulin-stimulated tissue BCAA utilization with
insulin resistance [17]. LaFerrere and colleagues reported that
blood BCAA tracked insulin resistance indices regardless of weight
loss [11]. Differences in outcomes between those reports and ours
may stem from our use of a controlled feeding paradigm prior to
blood sampling, and fitness improvement coupled to weight loss.
Regardless, we conclude that blood BCAA and 2-HB do not
always track changes in insulin resistance status in humans, and
the associations may be context-specific.
Other reported markers of insulin resistance or T2D primarily
from cross-sectional studies include increased fasting blood or
urine stearoyl-CoA desaturase-derived fatty acids, glucose deriv-
atives and gluconeogenic precursors, bile acids or derivatives,
cystine-cysteine (e.g., [5,7,8,15,16,69,70]), and decreased glycine,
glutamine, L-GPC, and arachidonic acid (e.g., [5,7–
9,13,15,16,71]). Under conditions of a glucose challenge, individ-
uals with insulin resistance had a blunted response in terms of
blood lactate, bile acid or TCA-associated organic acid increases
and glycerol and b-hydroxybutyrate decreases [17,20]). Consistent
with these studies, we observed that improved metabolic health
and weight loss led to lower fasting lactate and pyruvate (possibly
reflective of more efficient oxidative metabolism of glucose),
reduced cystine (potentially indicating lower oxidative stress), and
higher fasting plasma glycine (unknown etiology, but possibly
related to reduced glycine conjugation load with more efficient
metabolism). Previously, we reported uridine (a component of
RNA metabolism, minor sugar derivatives, or diet) was elevated in
T2D [8], and in the current study fasting plasma levels of this
metabolite were reduced post-intervention and helped discrimi-
nate the pre- vs. post-intervention conditions. Thus, the direc-
tionalities of many metabolites in the current study are consistent
with expectations from prior reports. The specific origins of these
patterns and their connections with metabolic health phenotypes
require further study.
Strengths, Limitations and Future Directions
There were several limitations of the study. A select number of
plasma metabolite patterns were shifted with improved fitness,
weight loss, and insulin sensitivity, but this cannot confirm
phenotype cause-and-effect or metabolite site(s) of origin, espe-
cially since fecal samples were not collected. Furthermore, in the
current study design, one cannot deconvolute the main driver(s) of
the blood metabolite changes, e.g. weight loss and fitness vs.
insulin sensitivity. Strengths of the study included minimization of
variance through the use of a narrowly-defined cohort of women,
dynamic measurement of metabolites (post-OGTT, pre- and post-
intervention), and a blood sampling regimen comparing pre- and
post-intervention test weeks that were precisely-matched for diet,
physical activity levels, weight-maintenance and menstrual cycle
phase. The results highlight the importance of using uniform
dietary and challenge test conditions when interrogating biological
models with highly-sensitive metabolite analysis platforms. We do
acknowledge, however, that interpretations are limited to the
current subject population and conditions, and whether or not
they apply to the broader population will require further validation
studies. With respect to the observed xeno-metabolite patterns,
one may ask, ‘‘What are the host signals emanating from improved
insulin sensitivity, fitness or adiposity that influence gut function,
microbial ecology, and concomitant changes in xeno-metabolite
kinetics?’’ That we observed significant blood fasting and post-
OGTT xeno-metabolite changes following a weight loss and
fitness regimen under well-matched diet sampling conditions
emphasizes the critical importance of signals sensitive to host
metabolic physiology that direct the gut environment.
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